Suzhou Zelgen Biopharmaceutical Co., Ltd. (Stock Code: 688266), founded in 2009 and headquartered in the Kunshan National High-Tech Industrial Development Zone of Jiangsu Province, operates through four subsidiaries: Shanghai Zelgen Pharmaceutical Technology Co., Ltd., Suzhou Zelgen Biosciences Co., Ltd., Zelgen Pharmaceutical (Zhejiang) Co., Ltd., and Zelgen Holdings Limited. Zelgen is dedicated to the independent R&D, production, and commercialization of innovative drugs. The company aims to become a leading enterprise in the R&D and production of novel drugs in China for areas including oncology, autoimmune diseases, and hemostasis/hematology. Its market strategy is globally oriented yet focused on China, aiming to develop and produce innovative drugs with independent intellectual property rights that are safe, effective, and affordable for patients, thereby meeting significant unmet medical needs both domestically and internationally.

A robust pipeline of novel drugs is the cornerstone of the company's success. Leveraging extensive experience and expertise in drug R&D, Zelgen has successfully established two distinctive core technology platforms: the small molecule drug R&D platform and the bispecific/trispecific antibodies and complex recombinant proteins R&D platform. Utilizing these platforms, the company has developed a rich pipeline of small molecule and recombinant protein drug candidates. The R&D efforts cover multiple therapeutic areas, including advanced solid tumors (such as hepatocellular carcinoma, thyroid cancer, small cell lung cancer, neuroendocrine carcinoma, gallbladder cancer, cervical cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer) and hematological malignancies, as well as bleeding and immune-inflammatory diseases.

Zelgen has successfully completed five national "Major New Drug Innovation" projects, one National Technology Innovation Fund for Small and Medium-Sized Technology-Based Enterprises, and several provincial-level scientific and technological projects in Jiangsu. As of September 30, 2025, the company had filed a total of 390 patent applications, with 136 invention patents granted in China, the United States, the European Union, and other countries and regions.

We have four marketed drugs: Zepsun® (Donafenib Tosilate Tablets), China's first domestically developed small molecule multi-target drug for the first-line treatment of advanced hepatocellular carcinoma; Zepuping® (Gecacitinib Hydrochloride Tablets), China's first domestically developed innovative JAK inhibitor for the treatment of myelofibrosis; Zepuning® (Recombinant Human Thrombin), the only recombinant human thrombin in China successfully commercialized using recombinant DNA technology; and Zesuning® (Human Thyrotropin Beta for Injection), China's first approved innovative product for postoperative precise assessment of differentiated thyroid cancer, used as a diagnostic drug for radioactive iodine whole-body scanning and serum thyroglobulin testing during postoperative follow-up for patients with differentiated thyroid cancer.

Our candidate drug pipeline includes over 10 candidates, encompassing further clinical programs related to Zepuping® for autoimmune diseases, as well as projects targeting novel mechanisms or employing breakthrough technologies, such as ZG006 (Alveltamig) and ZG005 (Nilvanstomig). Furthermore, we are building a portfolio of cutting-edge early-stage projects, including ZGGS18, ZGGS34, ZGGS15, ZG2001, ZG0895, ZG016, and ZG2273, covering T-cell engagers, bispecific and multispecific antibodies, and small molecule therapies targeting traditionally "undruggable" targets.

Zelgen has two R&D centers located in Kunshan, Jiangsu, and Zhangjiang, Shanghai. Our R&D team comprises experts with extensive experience across the entire drug development cycle, including drug discovery, CMC research, preclinical development, clinical development, regulatory affairs, and post-marketing studies.

At Zelgen's Kunshan Headquarter, GMP production facilities for oral solid dosage forms of chemical drugs and for recombinant protein drugs have been established. The company has obtained drug manufacturing licenses for tablets, capsules, and 2 recombinant protein drugs. The completion of these two major industrialization platforms will ensure Zelgen possesses more flexible production and supply capabilities and enhanced cost-control advantages.